Literature DB >> 3495958

Schizophrenia: lifetime co-morbidity in a community sample.

R C Bland, S C Newman, H Orn.   

Abstract

Twenty persons with schizophrenia were identified in a community sample of 2144 adult household residents interviewed by trained lay interviewers using the Diagnostic Interview Schedule. The hierarchy-free lifetime prevalence for a variety of psychiatric disorders is compared in those with and without schizophrenia. Those with schizophrenia were found to have increased chances of having other disorders, all except one having had at least one other disorder. Major depressive episodes, obsessive compulsive disorder, phobia, alcohol abuse/dependence and drug abuse/dependence, each occurred in over half of the schizophrenics, and panic disorder, antisocial personality, and mania were each found in one sixth to one quarter of the schizophrenics. Although current diagnostic systems generally lack an empirical basis for hierarchies, the practical significance of co-morbidity must be determined from outcome studies, familial morbid risk data and possible differential effects of treatments.

Entities:  

Mesh:

Year:  1987        PMID: 3495958     DOI: 10.1111/j.1600-0447.1987.tb02806.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  19 in total

Review 1.  Anxiety in Patients with Schizophrenia: Epidemiology and Management.

Authors:  Henk Temmingh; Dan J Stein
Journal:  CNS Drugs       Date:  2015       Impact factor: 5.749

2.  Attacking Heterogeneity in Schizophrenia by Deriving Clinical Subgroups From Widely Available Symptom Data.

Authors:  Dwight Dickinson; Danielle N Pratt; Evan J Giangrande; MeiLin Grunnagle; Jennifer Orel; Daniel R Weinberger; Joseph H Callicott; Karen F Berman
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

3.  Conduct disorder and antisocial personality disorder in persons with severe psychiatric and substance use disorders.

Authors:  Kim T Mueser; Anne G Crocker; Linda B Frisman; Robert E Drake; Nancy H Covell; Susan M Essock
Journal:  Schizophr Bull       Date:  2006-03-30       Impact factor: 9.306

4.  Aging and outpatient service use among persons with schizophrenia-spectrum disorders in a statewide behavioral healthcare system.

Authors:  Weili Lu; Philip T Yanos; Shula Minsky; Gerard L Kiely
Journal:  J Behav Health Serv Res       Date:  2004 Oct-Dec       Impact factor: 1.505

Review 5.  Cannabis-associated psychosis: current status of research.

Authors:  F Markus Leweke; Christoph W Gerth; Joachim Klosterkötter
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  Obsessive-compulsive disorder in schizophrenia: epidemiologic and biologic overlap.

Authors:  P Tibbo; L Warneke
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

Review 7.  How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association.

Authors:  Amélie M Achim; Michel Maziade; Eric Raymond; David Olivier; Chantal Mérette; Marc-André Roy
Journal:  Schizophr Bull       Date:  2009-12-03       Impact factor: 9.306

Review 8.  Prevalence of alcohol and drug abuse in schizophrenic inpatients.

Authors:  M Soyka; M Albus; N Kathmann; A Finelli; S Hofstetter; R Holzbach; B Immler; P Sand
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

9.  Relation of schizophrenia prevalence to latitude, climate, fish consumption, infant mortality, and skin color: a role for prenatal vitamin d deficiency and infections?

Authors:  Dennis K Kinney; Pamela Teixeira; Diane Hsu; Siena C Napoleon; David J Crowley; Andrea Miller; William Hyman; Emerald Huang
Journal:  Schizophr Bull       Date:  2009-04-08       Impact factor: 9.306

Review 10.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.